This post originally appeared during market hours on the stock market forums – 3-30-11 We are seeing a bullish divergence intraday in Exelixis (EXEL), which can only happen as the stock downtrends.  That means the indicators are showing good signs beneath the price weakness (see chart).  While this is good news, this doesn’t make a [...]

This post originally appeared during market hours on the stock market forums – 3-30-11 We are seeing a bullish divergence intraday in Exelixis (EXEL), which can only happen as the stock downtrends.  That means the indicators are showing good signs beneath the price weakness (see chart).  While this is good news, this doesn’t make a [...]

Medivation (NADSAQ:MDVN) was once a thriving biotech with some of the most promising treatments for Alzheimer’s, Huntington Disease and Prostate cancer. Reaching an all-time high of $40 per share back in early 2010, the stock had investors on the edge of their seat in anticipation of what could become, but instead fell short as the [...]

Prostate cancer is the most common form of cancer among men, and two new companies in Medivation and Johnson & Johnson are leading the charge with their experimental new treatments. These two will highlight their findings at The American Society of Clinical Oncology (ASCO), a meeting which has quickly become one of the most important [...]

This was the bullish day we had been waiting for in Exelixis (EXEL).  We finally broke past some key resistance levels and now the bulls have the upper hand to push our way towards the next resistance at $12.50 and onto the 52-week highs shortly thereafter.  If the shorts start to cover at once, we [...]

Popularity in equities has never been higher than in 2011, with most analysts, including Hilary Kramer raving about the S&P 500 (NYSE:SPY) namely due to $2 trillion dollars worth of cash lying around on the balance sheets of companies. This leads to mergers and acquisitions, along with consolidations which run up prices with the US [...]

San Diego-based Optimer Pharmaceuticals has spent more than $200 million and a dozen years of effort to get to the point where it can ask the FDA to clear its first product for sale on the U.S. market. And that’s the position Optimer finds itself in now. The company has received little praise from the [...]

This week’s stock of the week is a biotech play we have been accumulating for a while now, Exelixis (EXEL).  Friday, EXEL saw very strong bullish volume paving the way for it to resume this week.  The shorts won’t give up without a fight though.  The following forum thread discusses and tracks the strategy from [...]

The following are the most discussed topics during our live chat over the past week and/or the most viewed topics on the forum this past week.  As some of you know, we just rolled out the brand new stock market forum recently.  These are utilized throughout the day for speed and efficiency reasons when writing [...]

With the Nikkei (Japan Market) finally rebounding tonight, the bulls are breathing a sigh of relief before Wednesday’s open.  Tuesday saw us break more support levels all the way down to the 100-day SMA before the dip-buyers went to work.  After hitting the support level and looking very oversold, we bounced all the way up [...]